Orchestra BioMed receives $15m Ligand tranche, totalling $40m
Orchestra BioMed has received a $15 million payment from Ligand Pharmaceuticals under the pair's previously disclosed royalty-based financing agreement, completing Ligand's $35 million royalty financing commitment and bringing the cumulative capital received from Ligand to $40 million. The Nasdaq-listed medical device developer said the funds will support ongoing pivotal trials for its two lead cardiovascular programmes: AVIM Therapy, a bioelectronic treatment for hypertension, and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a drug-delivery angioplasty device targeting atherosclerotic artery disease.
Combined with a separate $20 million payment from Medtronic — also received on 1 May 2026 under a pre-existing agreement — Orchestra BioMed collected $35 million in a single day. Both capital receipts were structured tranches under previously announced deals rather than new fundraising, a distinction that limits their signal value as a barometer of current investor appetite, though the timely receipt of scheduled payments does confirm that milestone conditions were met.
Programme progress
Todd Davis, chief executive of Ligand, cited several operational milestones since the initial $20 million tranche closed in August 2025: accelerating enrolment in the BACKBEAT pivotal study of AVIM Therapy, a partnership realignment with Terumo for the Virtue SAB programme, and the start of patient enrolment in the Virtue Trial. The BACKBEAT study is a randomised, controlled global pivotal trial evaluating AVIM Therapy — delivered via standard dual-chamber pacemakers — in patients with systolic hypertension who are also indicated for cardiac pacing. Pilot data from the earlier MODERATO II study showed reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months versus control.
Virtue SAB holds FDA Breakthrough Device Designation for three indications: coronary in-stent restenosis, coronary small vessel disease, and below-the-knee peripheral artery disease. AVIM Therapy holds two Breakthrough Device Designations for uncontrolled hypertension in pacemaker-indicated patients. Breakthrough Device status does not guarantee approval but enables more intensive FDA engagement during development.
Market and competitive context
The cardiovascular device market is fiercely contested. Established players including Medtronic, Abbott, and Boston Scientific dominate both the cardiac rhythm management and peripheral vascular segments, and Orchestra BioMed has structured its strategy explicitly around co-development agreements with those incumbents rather than competing head-on commercially. The Medtronic partnership covers the global development and commercialisation of AVIM Therapy; the Terumo relationship, now realigned, covers Virtue SAB.
The royalty-financing model used here — in which Ligand receives a tiered royalty interest in future revenue plus an equity stake — has become an increasingly common mechanism for capital-constrained device and biopharma developers to avoid dilutive equity rounds at early-stage valuations. Ligand itself describes its business model as royalty aggregation across more than 100 development and commercial-stage assets, meaning Orchestra BioMed's programmes compete for attention within a sizeable portfolio.
Key near-term catalysts for Orchestra BioMed will be interim enrolment data from both pivotal trials, any further regulatory interactions disclosed by the company, and the pace of the Terumo partnership realignment. Full pivotal readouts are not expected on a timeline specified in the current announcement; investors should monitor the company's forthcoming quarterly disclosures for updated guidance.